Pascal Deschatelets is Chief Scientific Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 1.14 Million shares of APLS, which is worth approximately $37.3 Million. The most recent transaction as insider was on May 08, 2023, when has been sold 12,000 shares (Common Stock) at a price of $92.39 per share, resulting in proceeds of $1,108,680. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.14M
0% 3M change
2.12% 12M change
Total Value Held $37.3 Million

Pascal Deschatelets Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 08 2023
SELL
Open market or private sale
$1,108,680 $92.39 p/Share
12,000 Reduced 1.15%
1,033,813 Common Stock
May 08 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.74%
1,045,813 Common Stock
Apr 10 2023
SELL
Open market or private sale
$938,519 $78.21 p/Share
12,000 Reduced 1.15%
1,027,313 Common Stock
Apr 10 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.75%
1,039,313 Common Stock
Mar 08 2023
SELL
Open market or private sale
$765,480 $63.79 p/Share
12,000 Reduced 1.16%
1,020,813 Common Stock
Mar 08 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.76%
1,032,813 Common Stock
Feb 21 2023
SELL
Payment of exercise price or tax liability
$69,907 $58.5 p/Share
1,195 Reduced 0.12%
1,014,313 Common Stock
Feb 21 2023
BUY
Grant, award, or other acquisition
-
9,886 Added 0.96%
1,015,508 Common Stock
Feb 10 2023
SELL
Payment of exercise price or tax liability
$58,072 $51.21 p/Share
1,134 Reduced 0.11%
1,005,622 Common Stock
Feb 08 2023
SELL
Open market or private sale
$653,400 $54.45 p/Share
12,000 Reduced 1.18%
1,006,756 Common Stock
Feb 08 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.78%
1,018,756 Common Stock
Jan 27 2023
SELL
Payment of exercise price or tax liability
$43,904 $52.77 p/Share
832 Reduced 0.08%
1,000,256 Common Stock
Jan 20 2023
SELL
Payment of exercise price or tax liability
$121,068 $52.05 p/Share
2,326 Reduced 0.23%
1,001,088 Common Stock
Jan 12 2023
BUY
Grant, award, or other acquisition
-
19,634 Added 1.92%
1,003,414 Common Stock
Jan 09 2023
SELL
Open market or private sale
$552,960 $46.08 p/Share
12,000 Reduced 1.21%
983,780 Common Stock
Jan 09 2023
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.82%
995,780 Common Stock
Dec 29 2022
BUY
Exercise of conversion of derivative security
$25,690 $3.67 p/Share
7,000 Added 0.71%
977,280 Common Stock
Dec 08 2022
SELL
Open market or private sale
$570,000 $47.5 p/Share
12,000 Reduced 1.22%
970,280 Common Stock
Dec 08 2022
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.85%
982,280 Common Stock
Nov 08 2022
SELL
Open market or private sale
$557,640 $46.47 p/Share
12,000 Reduced 1.23%
963,780 Common Stock
Nov 08 2022
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.86%
975,780 Common Stock
Oct 10 2022
SELL
Open market or private sale
$690,000 $57.5 p/Share
12,000 Reduced 1.24%
957,280 Common Stock
Oct 10 2022
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.87%
969,280 Common Stock
Sep 08 2022
SELL
Open market or private sale
$767,760 $63.98 p/Share
12,000 Reduced 1.25%
950,780 Common Stock
Sep 08 2022
BUY
Exercise of conversion of derivative security
$49,395 $2.67 p/Share
18,500 Added 1.89%
962,780 Common Stock
PD

Pascal Deschatelets

Chief Scientific Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS